Emma Andrus, Assistant Editor

The September 2023 issue of Dermatology Times featured a spotlight on psoriasis research, advances, and treatment options in patients with skin of color. Learn more about the topics covered in each spotlight article.

A patient with atopic dermatitis presents with redness and other unusual symptoms. What's the diagnosis?

Investigators reported successful treatment of psoriasis with risankizumab, despite presence of concomitant HIV infection in 4 male patients.

Raj Chovatiya, MD, PhD, shares his atopic dermatitis insights.

Keep up with the latest headlines in dermatology from the past week, including new research into artificial intelligence skin tone bias, dermatologic care of the unhoused patient population, and more.

Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.

Abeona Therapeutics is seeking Priority Review and approval of the therapy for patients with recessive dystrophic epidermolysis bullosa.

A single-arm, prospective trial found that botulinum toxin injections did not have a significant effect on symptoms one month after treatment.

Keep up with the latest headlines in dermatology from the past week, including efforts to raise awareness about the importance of skin checks and sun protection, CeraVe's role in expanding a dermatology residency training program, and more.

A systematic review found that generally, combination therapy has evidence supportive of its efficacy in hidradenitis suppurativa.

Today is National Native American Day. Dermatology Times is reviewing the unique dermatologic concerns and disparities faced by members of the Native and Indigenous communities.

Public health/public policy researcher and New York Times best-selling author Marty Makary, MD, MPH, FACS, discusses the role of physician-led legislative advocacy in health care and dermatology.

Among the many sessions to be held at the 2023 Science of Skincare Summit in Austin, Texas, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Prior research has demonstrated an association between religious headwear and traction alopecia.

Peter Lio, MD, offers perspectives on topical steroid withdrawal, also known as red skin syndrome or topical steroid addiction.

Investigators found a steady reduction of IgE levels in patients regardless of dupilumab dosing interval.

Clinicians can use culturally competent care to ease patients’ concerns with identity and better understand the emotional toll of the condition.

The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.

Affective, anxiety, and neurotic disorders were among the most common in a recent study.

This Skin Care Awareness Month, we want to hear more about your experiences with discussing skin care habits with your patients. Click to answer this week's poll.

Keep up with the latest headlines in dermatology from the past week, including advances in diversifying the specialty, artificial skin and its role in eczema research, and more.

This Hispanic Heritage Month, Dermatology Times is reviewing the unique dermatologic concerns and disparities faced by members of the Hispanic community.

In a study of 19 patients, the laser treatment led to excellent responses in 86.36% of participants, with 78.94% achieving complete response.

According to researchers, only 3 studies have previously explored a potential link between AD and dementia with inconsistent findings.

Indeterminacy of invisible subcutaneous lesions such as epidermoid cysts, lipomas, pilomatrixomas, hemangiomas, and DFSPs, can be decreased with HFUS use, according to investigators.

Nektar Therapeutics announced the promising and statistically significant results, which included meeting endpoints of BSA, DLQI and POEM in patients with atopic dermatitis.

Researchers compared the efficacy of the 2 modalities and found that they were equal in safety, efficacy, and tolerability.

The submission follows the announcement of recent long-term data of the drug in patients ages 6 years and older.

Steven Dayan, MD, FACS, first author behind a recent study involving high rates of patient satisfaction following treatment with botulinum toxin, discusses the importance of placing patient satisfaction at the forefront of cosmetic dermatology.